Antimicrobial Resistance and Molecular Characterization of \textit{Staphylococcus aureus} Recovered from Cows with Clinical Mastitis in Dairy Herds from Southeastern Brazil

Gustavo Freu, Tiago Tomazi, Antonio F. S. Filho, Marcos B. Heinemann, and Marcos V. dos Santos

Abstract: \textit{Staphylococcus aureus} is a contagious pathogen frequently associated with bovine mastitis in Brazil. Molecular characterization of \textit{Staph. aureus} isolated from affected mammary quarters of cows with clinical mastitis (CM) can provide data on epidemiological behavior of this pathogen and antimicrobial susceptibility (AMS) assessment at the genotypic level. This study genotypically characterized \textit{Staph. aureus} isolates recovered from cows with CM and determined the association of genotypes and AMS. A total of 84 \textit{Staph. aureus} strains identified from affected mammary quarters of cows with CM in 13 dairy herds from Southeastern Brazil were submitted for susceptibility testing to 10 antimicrobials using the technique of minimal inhibitory concentration. The same isolates were also genotyped using the spa-typing methodology. Results showed a high genotypic similarity among genotypic clusters, which may affect the efficacy of antimicrobials used to treat CM in different dairy herds.

Keywords: antimicrobial resistance; clinical mastitis; spa-typing; \textit{Staphylococcus aureus}

1. Introduction

Bovine mastitis is a common disease in dairy herds causing significant economic losses to the dairy industry [1]. \textit{Staphylococcus aureus} is a major pathogen of mastitis, which is mainly transmitted between cows by the contagious route, causing both subclinical and clinical mastitis (CM) [2,3]. Additionally, some strains comprising this species are considered a threat to public health [4].

Although the prevalence of \textit{Staph. aureus} has been reduced in US dairy herds [5,6], this pathogen remains a frequent cause of mastitis in countries with developing dairy industry, such as Brazil [7]. Epidemiological studies carried out worldwide report prevalences of \textit{Staph. aureus} ranging from 0 to 70.3% in dairy herds [8,9].

Molecular characterization of mastitis-causing pathogens allows monitoring of specific features at the strain level, such as transmission routes and antimicrobial resistance. Among available molecular typing techniques, spa-typing is a reproducible and affordable method, which differs from multi-locus sequence typing (MLST) method, in that spa-typing involves the typing of a single locus [10–12]. These characteristics make spa-typing a useful technique for assessing the genetic diversity of \textit{Staph. aureus} isolated from bovine mastitis [13,14].

There is a major public and animal health concern about infections caused by antimicrobial-resistant \textit{Staph. aureus} [13,15,16]. Antimicrobial therapy remains an important strategy...
for treatment of CM caused by *Staph. aureus*, especially in dairy farms treating all cases of the disease regardless of pathogen. However, the bacteriological cure rates of CM caused by *Staph. aureus* after antimicrobial therapy is usually low [2] and depends on characteristics associated with the cow, mastitis-causing strain, environment conditions and therapeutic protocol used to treat the disease [17]. These factors may result in greater use of antimicrobials in dairy herds, which in consequence, can contribute to the increase in *Staph. aureus* resistance to available commercial drugs.

Strains of *Staph. aureus* causing mastitis resistant to multiple antimicrobials have been identified in several countries [18,19], including Brazil [20]. However, there are limited data on antimicrobial resistance of *Staph. aureus* isolated from cows with CM at the genotypic level. Assessing the strain-level antimicrobial resistance of *Staph. aureus* causing CM in Brazil can advance the pharmaco-epidemiology knowledge about this pathogen, especially considering the overuse of antimicrobials reported for treatment of CM in that country [21].

Furthermore, the assessment of genetic distribution and resistance profile of *Staph. aureus* can help in understanding the dispersion of circulating clones causing CM, contribute to the use and development of effective interventions and management practices, and help in the identification of possible transmission routes [22]. Therefore, the objectives of this study were: (a) to characterize the genotypic diversity of *Staph. aureus* isolated from affected mammary quarters of cows with CM in 13 dairy herds; and (b) determine the association between *Staph. aureus* resistance to antimicrobials according to the genetic similarity of strains.

2. Results

2.1. Descriptive Results and Spa-Typing

Of isolates initially cryopreserved (*n* = 112), 28 were not included in this study because of the following reasons: 11 did not grow when re-cultured for antimicrobial susceptibility testing, 8 were contaminated, 6 were isolated from repeated cases of CM within 14 days, and 3 did not have the species confirmed by MALDI-TOF MS (i.e., MALDI score < 2.0). Therefore, 84 *Staph. aureus* isolates from 13 dairy herds were evaluated in this study (Table 1). Detailed characteristics of the herds are described elsewhere [7].

Selected isolates were identified from affected mammary quarters of cows with CM housed in free stalls (*n* = 28, 33.0%), compost bedded pack barn (26.2%; *n* = 22), and grazing paddocks (40.5%; *n* = 34). In addition, 58 isolates (69.0%) were identified from mild cases of CM, whereas 22 (26.2%) were from moderate cases and only one (1.2%) from a severe case of CM. For 3 isolates (3.6%), the CM severity was not registered at the CM diagnosis (Table 1).

The DNA of eight isolates did not amplify during PCR, and therefore, the dendrogram was generated with the spa-typing profiles of 76 isolates (Figure 1). Four clusters (I, II, III and IV) were identified according to the genetic similarity of *Staph. aureus* isolates. Cluster I was composed of 32 isolates and had four spa-types (t). Cluster II had 39 isolates and had four spa-types. Clusters III and IV had only two isolates each and shared the same spa-types within clusters. Two isolates from cluster I and one isolate from cluster II did not have the spa-type recognized by the molecular method and were named in this study as “unclassified”. In addition, one isolate (named here as t037) had a lower level of similarity in comparison to other isolates and was not assigned into clusters (Table 1; Figure 1).

Of the 76 isolates with spa-typing results, the most prevalent types were t127 (*n* = 32; 42.1%) and t605 (*n* = 25; 32.9%; Figures 1 and 2). Based on the MST analysis, a high within- and between-herds similarity was observed among the isolates. For example, 12 of 15 isolates (80%) identified from cows with CM in the herd B pertained to the spa-type t605. Furthermore, 83.3% of *Staph. aureus* isolated in the herd E were classified as spa-types t605 (*n* = 6) and t127 (*n* = 4; Figure 2).
Table 1. Distribution of 84 *Staphylococcus aureus* isolates recovered from affected mammary quarters of cows with clinical mastitis according to spa-typing clusters, herd of origin, housing system, season, and severity score of clinical mastitis.

| Variable          | Categories | I  | II | III | IV | Spa-Type | Unclassified |
|-------------------|------------|----|----|-----|-----|----------|--------------|
|                   |            | n% | n% | n%  | n%  | n%       | n%           |
| Herd              |            | n  | n% | n%  | n%  | n%       | n%           |
| B (n = 15)        |            | 12 | 80.0 | 2 | 13.3 | - | 1 | 6.7 | - | - | - | - |
| C (n = 2)         |            | 1 | 50.0 | 1 | 50.0 | - | - | - | - | - | - | - |
| E (n = 12)        |            | 7 | 58.3 | 4 | 33.3 | 1.0 | 8.4 | - | - | - | - | - |
| F (n = 5)         |            | 3 | 60.0 | 1 | 20.0 | - | - | - | - | 1 | 20.0 | - |
| G (n = 2)         |            | 2 | 100.0 | - | - | - | - | - | - | - | - | - |
| H (n = 5)         |            | - | - | 5 | 100.0 | - | - | - | - | - | - | - |
| I (n = 1)         |            | - | - | - | - | - | - | - | 1 | 100.0 | - | - |
| J (n = 1)         |            | - | - | 1 | 100.0 | - | - | - | - | - | - | - |
| K (n = 3)         |            | - | - | 3 | 100.0 | - | - | - | - | - | - | - |
| L (n = 25)        |            | 4 | 16.0 | 13 | 52.0 | - | - | 1 | 4.0 | - | - | 7 | 28.0 |
| M (n = 2)         |            | - | - | - | - | - | - | - | - | - | - | - | - |
| O (n = 6)         |            | - | - | - | - | - | - | - | - | - | - | - | - |
| P (n = 2)         |            | - | - | 1 | 50.0 | 1.0 | 50.0 | - | - | - | - | - | - |
| T (n = 5)         |            | 3 | 60.0 | 2 | 40.0 | - | - | - | - | - | - | - | - |
| Housing           |            | n   | n%  | n%  | n%  | n%       | n%           |
| CBPB (n = 22)     |            | 15 | 68.1 | 5 | 22.7 | - | - | 1 | 4.6 | 1 | 4.6 | - | - |
| Freestall (n = 28)|            | 4 | 14.3 | 16 | 57.1 | - | - | 1 | 3.6 | - | - | 7 | 25.0 |
| Paddocks (n = 34) |            | 13 | 38.3 | 18 | 52.9 | 2 | 5.9 | - | - | 1 | 3.2 | 3 | 9.7 |
| Season            |            | n   | n%  | n%  | n%  | n%       | n%           |
| Rainy (n = 53)    |            | 18 | 34.0 | 27 | 50.9 | 1 | 1.9 | 2 | 3.8 | - | - | - | 5 | 9.4 |
| Dry (n = 31)      |            | 14 | 45.2 | 12 | 38.7 | 1 | 3.2 | - | - | 1 | 3.2 | - | - |
| CM severity       |            | n   | n%  | n%  | n%  | n%       | n%           |
| Mild (n = 58)     |            | 23 | 39.7 | 25 | 43.1 | 1 | 1.7 | 2 | 3.5 | - | - | - | 7 | 12.0 |
| Moderate (n = 22) |            | 7 | 31.8 | 12 | 54.5 | 1 | 4.6 | - | - | 1 | 4.6 | - | 4 | 4.5 |
| Severe (n = 1)    |            | - | - | 1 | 100.0 | - | - | - | - | - | - | - | - |
| No severity       |            | 2 | 66.7 | 1 | 33.3 | - | - | - | - | - | - | - | - |

1 Isolates that were not identified by the spa-typing method; 2 Housing system of herds from which the *Staph. aureus* isolates were selected; 3 CBPB: Compost bedded pack barn. 4 Clinical mastitis severity was recorded as mild, moderate and severe according to Wenz et al. [23]; 5 Isolates that did not have record of CM severity.

2.2. Overall Antimicrobial Susceptibility Testing

MIC results and the characterization of all *Staph. aureus* isolates as susceptible or resistant to antimicrobials are shown in Table 2. More than 50.0% of isolates were resistant to erythromycin (54.8%) and penicillin (60.7%). On the other hand, high susceptibility to sulfadimethoxine (100.0%) and oxacillin (88.0%) was observed between isolates. For the remaining antimicrobials, the susceptibilities were: cephalothin (77.4%), ceftiofur (69.0%), penicillin + novobiocin (60.7%), pirlimycin (61.9%), ampicillin (51.2%) and tetracycline (51.2%).

Table 2. Overall antimicrobial susceptibility of 84 *Staphylococcus aureus* strains isolated from affected mammary quarters of cows with clinical mastitis in 13 Brazilian dairy herds.

| Antimicrobial | Frequency (%) of *Staph. aureus* Isolates at Each Indicated MIC (µg/mL) | MIC50 | MIC90 |
|---------------|-------------------------------------------------|-------|-------|
|               | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 |       |       |
| Ampicillin    | 44.1 | 7.1 | 17.9 | 11.9 | 8.3 | 3.6 | 7.1 | - | - | - | - | - | 0.25 | 4 |
| Cefotiofur    | - | - | - | - | - | - | - | - | - | - | - | - | 2 | 4 |
| Cephalothin   | - | - | - | 11.9 | 32.1 | 25.0 | 31.0 | - | - | - | - | - | 2 | 16 |
| Erythromycin  | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 4 |
| Oxacillin     | - | - | - | - | - | 88.1 | 11.9 | - | - | - | - | - | 2 | 4 |
| Penic + Novobob | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 8 |
| Penicillin    | 39.3 | 8.3 | 14.3 | 12.0 | 10.7 | 7.1 | 8.3 | - | - | - | - | - | - | 0.5 | 4 |
| Pirlimycin    | - | - | - | - | - | 48.8 | 9.5 | 3.6 | 38.1 | - | - | - | - | - | 1 | 4 |
| Sulphadimet.  | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 8 |
| Tetracycline  | - | - | - | - | - | 16.7 | 21.4 | 13.1 | 45.8 | - | - | - | - | - | 4 | 8 |

1 The light gray shading represents the susceptible zone, and the darker gray shading represents the resistant zone. Results were interpreted according to CLSI [24,25]. Interpretative criteria were based on human data (ampicillin, cephalothin, erythromycin, oxacillin, penicillin, sulfadimethoxine and tetracycline), and bovine mastitis (ceftiofur, penicillin + novobiocin and pirlimycin). The resistant category included isolates categorized as either intermediate or resistant; 2 MIC (µg/mL) that inhibited 50% (MIC50) of the isolates; 3 MIC (µg/mL) that inhibited 90% (MIC90) of the isolates.
Figure 1. Clusters of spa-typing profiles of 76 Staph. aureus recovered from affected mammary quarters of cows with clinical mastitis in 13 dairy herds in Brazil. The data is presented according to the spa-typing classification, farm of origin, severity score of clinical mastitis, housing system used in the herd of origin, and season of clinical mastitis identification. For three isolates, the spa-type was unclassified (named here as “unknown”), and one isolate (*t037) was not assigned to any cluster.
Figure 2. Minimum spanning tree (MST) showing 76 *Staphylococcus aureus* isolates recovered from affected mammary quarters of cows with clinical mastitis and genotyped using the spa-typing method. Each node represents one spa-type, and the corresponding spa-type is given beside the node. The distribution of spa-types within herds are represented by colors. Lengths ≤ 1 are represented by dotted lines while lengths >1 by solid lines. Three isolates did not have spa-type recognized by the molecular method.

### 2.2. Overall Antimicrobial Susceptibility Testing

MIC results and the characterization of all *Staph. aureus* isolates as susceptible or resistant to antimicrobials are shown in Table 2. More than 50.0% of isolates were resistant to erythromycin (54.8%) and penicillin (60.7%). On the other hand, high susceptibility to sulfadimethoxine (100.0%) and oxacillin (88.0%) was observed between isolates. For the remaining antimicrobials, the susceptibilities were: cephalothin (77.4%), ceftiofur (69.0%), penicillin + novobiocin (60.7%), pirlimycin (61.9%), ampicillin (51.2%) and tetracycline (51.2%).

### 2.3. Antimicrobial Susceptibility Testing of Genotypic Clusters

Because of the low frequency of isolates in the clusters III and IV, the antimicrobial susceptibility was compared only between clusters I and II (Table 3). *Staph. aureus* isolates belonging to cluster I were more likely to be resistant to ampicillin than isolates from cluster II (OR = 0.27; CI: 0.09–0.87; *p* = 0.03). In addition, isolates belonging to cluster I tended to be more resistant to penicillin (*p* = 0.07) and less resistant to cephalothin (*p* = 0.09) when compared to isolates from cluster II.

For the remained antimicrobials evaluated, there was no significant difference (*p* > 0.05) in antimicrobial susceptibility between clusters.
Table 3. Results of the regression models comparing the antimicrobial susceptibility of 71 Staph. aureus strains isolated from affected mammary quarters of cows with clinical mastitis according to their genetic similarity into spa-typing clusters I (n = 32) and II (n = 39).

| Antimicrobial | Resistance 1 (LSM 2, %) | Odds Ratio (95% CI 3) | p-Value | MIC₅₀ 4 | MIC₉₀ 5 |
|---------------|-------------------------|-----------------------|---------|--------|--------|
|               | Cluster I | Cluster II | | Cluster I | Cluster II | Cluster I | Cluster II |
| Ampicillin     | 57.4      | 26.8      | 0.27 (0.09, 0.87) | 0.03 | 0.5 | 0.12 | 4 | 4 |
| Ceftiofur      | 44.9      | 28.4      | 0.49 (0.17, 1.41) | 0.18 | 1 | 2 | 4 | 4 |
| Cephalothin    | 13.2      | 29.9      | 2.80 (0.82, 9.56) | 0.09 | 2 | 4 | 16 | 16 |
| Erythromycin   | 58.5      | 52.6      | 0.79 (0.26, 2.36) | 0.67 | 1 | 1 | 4 | 4 |
| Oxacillin      | 9.4       | 7.7       | 0.81 (0.15, 4.45) | 0.80 | 2 | 2 | 2 | 2 |
| Penicillin     | 75.2      | 49.3      | 0.32 (0.09, 1.11) | 0.07 | 2 | 1 | 8 | 8 |
| Penic + Novob  | 50.2      | 32.8      | 0.48 (0.18, 1.31) | 0.15 | 0.5 | 0.25 | 4 | 8 |
| Pirlimycin     | 45.8      | 38.4      | 0.74 (0.25, 2.17) | 0.57 | 2 | 1 | 4 | 4 |
| Sulfadimethoxine | 92.3   | 95.5      | 1.78 (0.21, 15.27) | 0.59 | 256 | 256 | 256 | 256 |
| Tetracycline   | 56.3      | 52.2      | 0.85 (0.29, 2.43) | 0.75 | 8 | 4 | 8 | 8 |

1 The interpretation criteria to categorize the isolates as resistant were based on guidelines of CLSI [24,25]. Interpretative criteria were based on human data (ampicillin, cephalothin, erythromycin, oxacillin, penicillin, sulfadimethoxine and tetracycline), and bovine mastitis (ceftiofur, penicillin + novobiocin and pirlimycin). The resistant category included isolates categorized as either intermediate or resistant; 2 Least square means; 3 95% confidence interval; 4 MIC (µg/mL) that inhibited 50% (MIC₅₀) of the isolates; 5 MIC (µg/mL) that inhibited 90% (MIC₉₀) of the isolates.

3. Discussion

*Staph. aureus* remains an important cause of mastitis in dairy herds around the world that causes significant losses to the dairy industry [26]. This study evaluated the genotypic diversity and antimicrobial resistance of *Staph. aureus* isolated from affected mammary quarters of cows with CM in 13 dairy herds in Brazil. Our results showed high genetic similarity in protein A gene between *Staph. aureus* isolated from cows with CM within and among selected herds. In addition, resistance was observed to most antimicrobials evaluated, except for sulfadimethoxine.

The *Staph. aureus* strains enrolled in our study showed variable frequencies of resistance to the antimicrobials studied, with more than 50.0% of the isolates resistant to erythromycin (54.8%) and penicillin (60.7%). Similar to our results, a recent meta-analysis evaluating data from different countries reported that mastitis-causing *Staph. aureus* had the highest frequencies of resistance to penicillin and erythromycin among several antimicrobials tested in the studies selected for the systematic review [27]. The mechanisms by which *Staph. aureus* develops resistance to antimicrobials are variable and well-studied [26,28,29]. However, one of the possible factors triggering the resistance of mastitis-causing *Staph. aureus* may be overuse of antimicrobials to treat mastitis. A recent study reported a high frequency of antimicrobial use for treatment of CM in dairy herds in Brazil [21], which included the 13 herds from which our strains originated. According to the latter study, intensive therapeutic protocols such as combined and extended therapy are broadly used for treatment of CM in Brazil, which may explain the in vitro resistance of *Staph. aureus* strains observed in the present study.

All isolates in our study were susceptible to sulfadimethoxine, which was higher than reported in another study using the same method as we used to test the antimicrobial susceptibility of mastitis-causing *Staph. aureus* (75%; [30]). It is important to mention that direct comparisons between studies can be problematic, as the use of antimicrobials (quantitatively and qualitatively) in different regions can be affected by factors such as the incidence and etiology of CM in the enrolled herds, cost of therapy, and commercially available antimicrobials for treating mastitis. For example, there is no label use of sulfonamides for treatment of mastitis in the US, while in Brazil this antimicrobial is widely used (e.g., by intramammary and/or systemically route; [21]). High resistance to sulfadimethoxine has been reported in *Staph. aureus* strains isolated in Latin American herds [27], which may be associated with the high use of this antimicrobial in dairy herds for treatment of infectious
diseases. However, it is important to mention that sulfadimethoxine is a long-lasting sulfonamide not commonly recommended for the treatment of *Staph. aureus* causing mastitis. Although the resistance of *Staph. aureus* to sulfadimethoxine is reported in the literature, our results showed the opposite (100% sensitivity). It is important mentioning that in vitro studies may yield different results than in vivo studies, which may be associated with specific *Staph. aureus* features such as its capacity to invade the mammary gland cells, and form biofilm and micro-abscesses [2,31], which do not occur in tests performed in vitro.

Twelve percent of isolates in our study were resistant to oxacillin. Our result is higher than the 2.9% reported in North American dairy herds [30], but similar to that found in Chinese herds (12%; [32]). Although oxacillin is not approved for mastitis treatment in the US and Brazil, resistance to this antibiotic has been used as an indicator of methicillin-resistant *Staph. aureus* (MRSA) [32,33]. The frequency of MRSA isolated from milk samples from cows with mastitis is historically low [33], although an increase in the frequency of oxacillin-resistant bacteria has been reported over the past 50 years [27]. Implementing preventive measures to control mastitis caused by *Staph. aureus* can help prevent the spread of MRSA in dairy herds, once MRSA constitutes a risk factor for public health [34]. This can be especially important for Brazilian dairy herds where contagious pathogens are still a problem.

Our study found high genotypic similarity between *Staph. aureus* strains within and between selected herds. The majority of isolates were assigned to one of the two most prevalent clusters (I and II), in which two spa-types (t127 and t605) had the highest frequencies of identification. As extensively reported in previous studies, *Staph. aureus* is considered a major pathogen of mastitis, which is mainly transmitted by the contagious route [17,27,35]. The high genotypic similarity between strains in our study corroborate the latter statement. Similar and genetically close-related strains observed in our study may be the most prevalent *Staph. aureus* subspecies in selected herds, as they share the same geographic region (i.e., southeastern Brazil). According to Pacha et al. [36], common strains among dairy herds may indicate a dispersal source of *Staph. aureus*. In this case, herd biosecurity to reduce or eliminate the introduction of new strains and the movement of animals and the rotation of workers between farms are recognized as risk factor for spreading of *Staph. aureus* pathogenic strains [36,37]. As most of the herds in our study shared the same geographical region, the aforementioned events may have occurred, although it was not assessed herein.

According to the antimicrobial susceptibility comparison between the genotypic clusters, *Staph. aureus* belonging to cluster I were 0.27 times more resistant to ampicillin, and tended to be more resistant to penicillin and less resistant to cephalothin when compared to isolates belonging to cluster II. β-lactam antibiotics are among the most frequently used antimicrobials in dairy cows for treatment and/or prevention of mastitis [14,27,38]. In dairy herds in Brazil, β-lactam antibiotics are also among the most used compounds for treatment of CM, especially drugs administered systemically [21]. The overuse of β-lactam antibiotics may be one of the reasons associated with the overall resistance of *Staph. aureus* isolates to cephalosporins and penicillins in our study. In addition, differences in susceptibility observed between clusters may be associated with the presence of genetic differences among the isolates [39]. The higher resistance to ampicillin and penicillin in cluster I may be associated with genes expressing resistance to antibiotics of the penicillin class, which may be less frequent in strains belonging to cluster II. Genetic characterization studies evaluating the presence of specific resistance genes of strains can elucidate those matters, although such assessment was beyond the scope of our study.

The better understanding of the epidemiology of *Staph. aureus* genotypes can advance strategies to reduce the spread of infections. Some strains comprising the *Staph. aureus* species are considered a threat to public health [4]. Therefore, continuous antimicrobial susceptibility surveillance of *Staph. aureus* recovered from dairy cows is needed and can provide valuable information about changes in the resistance pattern of this pathogenic bacterium over time. The differences in antimicrobial susceptibility observed in our study
between *Staph. aureus* strains to specific antimicrobials used for mastitis control highlight the aforementioned. Therefore, strains presenting different responses to antimicrobials can vary the treatment outcomes within and between dairy herds.

The authors acknowledge that the number of isolates and herds evaluated in the current study is limited, however, our results can serve as reference for further large-scale studies evaluating genetic traits associated with antimicrobial resistance and presence of specific genetic features associated with the resistance of *Staph. aureus* causing bovine mastitis.

4. Materials and Methods

4.1. *Staphylococcus Aureus* Isolates

The isolates were identified in a previous study characterizing CM in 20 dairy herds of Southeastern Brazil [7]. During the latter study, 141 cases of CM were identified as caused by *Staph. aureus* using the techniques described in the National Mastitis Council guidelines [40], and 112 were cryopreserved (−80 °C) during the study period. Twenty-nine isolates were not cryopreserved because the species identification was based on a single colony, which prevented us from carrying out additional analyses to identify the species due to insufficient material to perform subcultures. Of the stored isolates, 84 were selected for this study based on the following inclusion criteria: (a) have pure microbiological growth at re-cultivation (i.e., no contamination), (b) isolated from a new case of CM (i.e., isolates from cows with repeated cases occurring before an interval of 14 days were excluded), and (c) identified at the species level by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), using identification score ≥ 2.0.

4.2. Antimicrobial Susceptibility Testing

The antimicrobial susceptibility of *Staph. aureus* isolates was performed according CLSI guidelines [24,25] and tested using a broth microdilution panel containing antimicrobials used for treatment of mastitis (Sensititre product CMV1AMAF, TREK Diagnostics, Cleveland, OH). The tests were performed according to the manufacturer’s recommendations and a total of 10 antimicrobials were evaluated: penicillin (0.12–8.0 µg/mL), ampicillin (0.12–8.0 µg/mL), oxacillin (2.0–4.0 µg/mL), cephalothin (2.0–16.0 µg/mL), cef- tiofur (0.5–4.0 µg/mL), penicillin + novobiocin (1.0/2.0–8.0/16.0 µg/mL), erythromycin (0.25–4.0 µg/mL), pirlimycin (0.5–4.0 µg/mL), tetracycline (1.0–8.0 µg/mL) and sulfadimethoxine (32.0–256.0 µg/mL). Strains from the American Type Culture Collection (ATCC; *Escherichia coli* 25,922 and *Staph. aureus*, 29,213) were assessed as quality controls.

The inoculum preparation and standardization of bacterial suspensions were performed as described by Tomazi et al. [41], with slight modifications. After preparation, 100 µL of the standardized bacterial inoculum was transferred in a tube containing 11 mL of Mueller-Hinton broth cation adjusted (pH = 7.3 ± 1; BD, Sparks, MD, USA) and vortexed by 10 s. Then 50 µL of bacterial suspension was added to each well of the Sensititre® panels, which were incubated at 37 °C for 20–24 h and read using the Sensititre® manual viewer (TREK Diagnostic Systems, LLC, Cleveland, OH, USA).

The lowest concentration of antimicrobials capable of inhibiting 50% (MIC₅₀) and 90% (MIC₉₀) of *Staph. aureus* isolates were determined for each antimicrobial. The isolates were characterized as susceptible, intermediate or resistant according to the CLSI guidelines [24,25]. Isolates characterized as intermediates were interpreted as resistant.

4.3. Spa-Typing

Prior genomic DNA extraction, a single colony was inoculated to 1.5 mL of Brain Heart Infusion broth and incubated at 37 °C for ~24 h. The suspension was centrifuged (15000 × g for 2 min; Mikro 200R, Hettich, Germany), the supernatant was discarded and the DNA was extracted using the Illustra bacteria genomicPrep Mini Spin Kit® (GE Healthcare, Buckinghamshire, United Kingdom) following the manufacturer’s guidelines. The quality of the extracted DNA was assessed by measuring the absorbances at 260 nm and 280 nm using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
The repeated region of the protein A gene was amplified according to Harmsen et al. [42]. The DNA sequences were obtained with an ABI-3500 automatic sequencer (Applied Biosystems®, Foster, CA, USA). Spa-types were determined with the protocol recommended by the Ridom spa Server (http://www.spaserver.ridom.de; accessed on 6 July 2017) and spa-type sequences were analyzed using the spa plugin included in Bionumerics 7.6 (Applied Maths NV, Sint-Martens-Latem, Belgium).

4.4. Data Analysis

The software JMP PRO 13 (SAS Institute Inc., Cary, NC, USA) was used for descriptive statistics. The spa-types distribution was assessed according to the farm from which the strain was isolated, CM severity and season of CM diagnosis (dry: April to September; rainy: October to March; [7]). The severity of CM was defined as: (mild) changes only in the milk appearance; (moderate) presence of abnormal milk accompanied by changes in the udder; or (severe) combination of abnormal milk, with signs of inflammation in the udder and systemic signs [23].

Clustering analysis was performed based on the Dice coefficient and the unweighted pair group method with arithmetic mean (UPGMA) using BioNumerics software v. 7.6 (Applied Maths, Sint-Martens-Ladem, Belgium). The minimum-spanning tree (MST) was generated to assess the association of clustering patterns of the herd and spa-typing. MST presented is the one with the highest overall reliability score and was calculated using UPGMA associated with the priority rule and the bootstrap resampling.

Ten separate multivariate logistic regression models were created using the binary distribution of the GLIMMIX procedure of SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). For each antimicrobial comprising the broth microdilution panel, a model was created to evaluate the association between the genotypic clusters and antimicrobial susceptibility (susceptible or resistant). Herd was included as random effect in all models to control for potential herd-level confounders (e.g., differences in the drug use practices) on the antimicrobial susceptibility of isolates. Statistical significance was assumed at $p \leq 0.05$. Tendency to significance was considered if the $p$-value was between 0.05 and 0.10.

5. Conclusions

Molecular analysis using spa-typing showed high genetic similarity between Staph. aureus isolated from affected quarters of cows with CM within and among selected herds. Resistance was observed to most antimicrobials evaluated, except for sulfadimethoxine. Considering the parameters used to generate the clusters based on the genotypic similarity of strains, Staph. aureus belonging to cluster I were more resistant to penicillin-based antimicrobials (i.e., ampicillin and penicillin) compared to cluster II. On the other hand, isolates belonging to cluster I tended to be less resistant to cephalothin compared to cluster II.

Author Contributions: Conceptualization, T.T. and M.V.d.S.; methodology, G.F., T.T., A.F.S.F., M.B.H. and M.V.d.S.; software, A.F.S.F., M.B.H. and T.T.; validation, G.F. and T.T.; formal analysis, G.F. and T.T.; investigation, G.F., T.T., A.F.S.F., M.B.H. and M.V.d.S.; resources, T.T. and M.V.d.S.; data curation, T.T.; writing—original draft preparation, G.F. and T.T.; writing—review and editing, A.F.S.F., M.B.H. and M.V.d.S.; visualization, A.F.S.F. and M.B.H.; supervision, M.V.d.S.; project administration, T.T. and M.V.d.S.; funding acquisition, M.V.d.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved by the Ethics Committee on Animal Use of the School of Veterinary Medicine and Animal Science of University of São Paulo (registration code: CEUA 2994060214).

Informed Consent Statement: Not applicable.
Data Availability Statement: All datasets are available from the corresponding author on reasonable request.

Acknowledgments: We are grateful to Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; Grant numbers 2013/22286-3, 2014/17411-6, and 2015/10332-6) and to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; Grant number 448357/2014-3) for financial support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hogeveen, H.; Van Der Voort, M. Assessing the economic impact of an endemic disease: The case of mastitis. Rev. Sci. Tech. 2017, 36, 217–226. [CrossRef] [PubMed]

2. Keefe, G. Update on control of Staphylococcus aureus and Streptococcus agalactiae for management of mastitis. Vet. Clin. Food Anim. Pract. 2012, 28, 203–216. [CrossRef] [PubMed]

3. Veh, K.A.; Klein, R.C.; Ster, C.; Keefe, G.; Lacasse, P.; Scholl, D.; Roy, J.P.; Haine, D.; Dufour, S.; Talbot, B.G.; et al. Genotypic and phenotypic characterization of Staphylococcus aureus causing persistent and nonpersistent subclinical bovine intramammary infections during lactation or the dry period. J. Dairy Sci. 2015, 98, 155–168. [CrossRef] [PubMed]

4. Guo, Y.; Song, G.; Sun, M.; Wang, J.; Wang, Y. Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus. Front. Cell. Infect. Microbiol. 2020, 10, 107. [CrossRef] [PubMed]

5. Oliveira, L.; Hulland, C.; Ruegg, P.L. Characterization of clinical mastitis occurring in cows on 50 large dairy herds in Wisconsin. J. Dairy Sci. 2013, 96, 7538–7549. [CrossRef] [PubMed]

6. Ruegg, P.L. A 100-year review: Mastitis detection, management, and prevention. J. Dairy Sci. 2017, 100, 10381–10397. [CrossRef]

7. Tomazi, T.; Ferreira, G.C.; Orsi, A.M.; Gonçalves, J.L.; Ospina, P.A.; Nydam, D.V.; Moroni, P.; Santos, M.V. Association of herd-level risk factors and incidence rate of clinical mastitis in 20 Brazilian dairy herds. Prev. Vet. Med. 2018, 161, 9–18. [CrossRef]

8. Dittmann, K.K.; Chaul, L.T.; Lee, S.H.I.; Corassin, C.H.; Fernandes de Oliveira, C.A.; Pereira De Martinis, E.C.; Alves, V.F.; Gram, L.; Oxaram, V. Staphylococcus aureus in some brazilian dairy industries: Changes of contamination and diversity. Front. Microbiol. 2017, 8, 2049. [CrossRef]

9. Mesquita, A.A.; Rocha Christian, M.B.M.; Bruhn, F.R.P.; Custódio, D.A.C.; Braz, M.S.; Pinto, S.M.; Silva, D.B.; Costa, G.M. Staphylococcus aureus and Streptococcus agalactiae: Prevalence, resistance to antimicrobials, and their relationship with the milk quality of dairy cattle herds in Minas Gerais state, Brazil. Pesqui. Veterinaria Bras. 2019, 39, 308–316. [CrossRef]

10. Hallin, M.; Deplano, A.; Denis, O.; de Mendoza, R.; de Ryck, R.; Struelens, M.J. Validation of pulsed-field gel electrophoresis and spa typing for long-term, nationwide epidemiological surveillance studies of Staphylococcus aureus infections. J. Clin. Microbiol. 2007, 45, 127–131. [CrossRef]

11. Strommenger, B.; Braulke, C.; Heuck, D.; Schmidt, C.; Pasemann, B.; Nübel, U.; Witte, W. Spa typing of Staphylococcus aureus as a frontline tool in epidemiological typing. J. Clin. Microbiol. 2008, 46, 574–581. [CrossRef] [PubMed]

12. Sabat, A.J.; Budimir, A.; Nashev, D.; Sá-Leão, R.; van Dijl, J.M.; Laurent, F.; Grundmann, H.; Friendrich, A.W. Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Eurosurveillance 2013, 18, 20380. [CrossRef] [PubMed]

13. Bonsaglia, E.C.R.; Silva, N.C.C.; Rossi, B.F.; Camargo, C.H.; Dantas, S.T.A.; Langoni, H.; Guimarães, F.F.; Lima, F.S.; Fritzgerald, J.R.; Fernandes Junior, A.; et al. Molecular epidemiology of methicillin-susceptible Staphylococcus aureus (MSSA) isolated from milk of cows with subclinical mastitis. Microb. Pathog. 2018, 124, 130–135. [CrossRef]

14. Mora-Hernández, Y.; Vera Murguia, E.; Stinenbosch, J.; Hernández Jauregui, P.; van Dijl, J.M.; Buist, G. Molecular typing and antimicrobial resistance profiling of 33 mastitis-related Staphylococcus aureus isolates from cows in the Comarca Lagunera region of Mexico. Sci. Rep. 2021, 11, 6912. [CrossRef]

15. Deyno, S.; Fekadu, S.; Astatkie, A. Resistance of Staphylococcus aureus to antimicrobial agents in Ethiopia: A meta-analysis. Antimicrob. Resist. Infect. Control 2017, 6, 85. [CrossRef] [PubMed]

16. da Silva Abreu, A.C.; Matos, L.G.; da Silva Cândido, T.J.; Barboza, G.R.; de Souza, V.V.M.A.; Munive Nuñez, K.V.; Silva, N.C.C. Antimicrobial resistance of Staphylococcus spp. isolated from organic and conventional Minas Frescal cheese producers in São Paulo, Brazil. J. Dairy Sci. 2021, 104, 4012–4022. [CrossRef]

17. Barkema, H.W.; Schukken, Y.H.; Zadoks, R.N. Invited review: The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus. J. Dairy Sci. 2006, 89, 1877–1895. [CrossRef]

18. Wang, X.; Wang, X.; Wang, Y.; Guo, G.; Usman, T.; Hao, D.; Tang, X.; Zhang, Y.; Yu, Y. Antimicrobial resistance and toxin gene profiles of Staphylococcus aureus strains from Holstein milk. Lett. Appl. Microbiol. 2014, 58, 527–534. [CrossRef]

19. Salauddin, M.; Akter, M.R.; Hossain, M.K.; Nazir, K.H.M.N.H.; Noreddin, A.; El Zowalty, M.E. Molecular detection of multidrug resistant Staphylococcus aureus isolated from bovine mastitis milk in Bangladesh. Vet. Sci. 2020, 7, 36. [CrossRef]

20. Fontana, V.L.D.da.S.; Giannini, M.J.S.M.; Leite, C.Q.F.; Miranda, E.T.; Almeida, A.M.F.; Fontana, C.A.P. Etiology of bovine subclinical mastitis, susceptibility of the agents to antimicrobial drugs and detection of the gene [beta]-lactamase in Staphylococcus aureus. Vet. Zootec. 2010, 17, 552–560.

21. Tomazi, T.; dos Santos, M.V. Antimicrobial use for treatment of clinical mastitis in dairy herds from Brazil and its association with herd-level descriptors. Prev. Vet. Med. 2020, 176, 104937. [CrossRef] [PubMed]
22. Li, T.; Lu, H.; Wang, X.; Gao, Q.; Dai, Y.; Shang, J.; Li, M. Molecular characteristics of Staphylococcus aureus causing bovine mastitis between 2014 and 2015. *Front. Cell. Infect. Microbiol.* **2017**, *7*, 127. [CrossRef] [PubMed]

23. Wenz, J.R.; Garry, F.B.; Barrington, G.M. Comparison of disease severity scoring systems for dairy cattle with acute coliform mastitis. *J. Anim. Vet. Med. Assoc.* **2006**, *22*, 259–262. [CrossRef] [PubMed]

24. CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals*, 4th ed.; Approved Guideline: Document VET01-S2; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2013.

25. CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals*, 3rd ed.; Approved Guideline: Document M100-S25; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2015.

26. Vaughn, J.M.; Abdi, R.D.; Gillespie, B.E.; Kerro Dego, O. Genetic diversity and virulence characteristics of *Staphylococcus aureus* isolates from cases of bovine mastitis. *Rev. Sci. Tech.-OIE* **2006**, *24*, 104171. [CrossRef]

27. Molineri, A.I.; Camussonese, C.; Zbrun, M.V.; Suárez Archilla, G.; Cristiani, M.; Neder, V.; Calvinho, L.; Signorini, M. Antimicrobial resistance of *Staphylococcus aureus* isolated from bovine mastitis: Systematic review and meta-analysis. *Prev. Vet. Med.* **2021**, *188*, 105261. [CrossRef]

28. Wang, D.; Zhang, L.; Zhou, X.; He, Y.; Yong, C.; Shen, M.; Szenci, O.; Han, B. Antimicrobial susceptibility, virulence genes, and randomly amplified polymorphic DNA analysis of *Staphylococcus aureus* recovered from bovine mastitis in Ningxia, China. *J. Dairy Sci.* **2016**, *99*, 9560–9569. [CrossRef]

29. Rossi, B.F.; Bonsaglia, E.C.R.; Castilho, I.G.; Dantas, S.T.A.; Salina, A.; Langoni, H.; Pantoja, J.C.F.; Fitzgerald-Hughes, A.; Fernandes Júnior, A.; et al. Genotyping of long term persistent *Staphylococcus aureus* in bovine subclinical mastitis. *Microb. Pathog.* **2019**, *132*, 45–50. [CrossRef]

30. Abdi, R.D.; Gillespie, B.E.; Vaughn, J.; Merrill, C.; Headrick, S.I.; Ensermu, D.B.; D’Souza, D.H.; Agga, G.E.; Almeida, R.A.; Oliver, S.P.; et al. Antimicrobial resistance of *Staphylococcus aureus* isolates from dairy cows and genetic diversity of resistant isolates. *Foodborne Pathog. Dis.* **2018**, *15*, 449–458. [CrossRef]

31. Pedersen, R.R.; Krömker, V.; Bjarnsholt, T.; Dahl-Pedersen, K.; Buhl, R.; Jørgensen, E. Biofilm research in bovine mastitis. *Front. Vet. Sci.* **2021**, *8*, 449. [CrossRef]

32. Pu, W.; Su, Y.; Li, J.; Li, C.; Yang, Z.; Deng, H.; Ni, C. High incidence of oxacillin-susceptible mecA-positive *Staphylococcus aureus* (OS-MRSA) associated with bovine mastitis in China. *PLoS ONE* **2014**, *9*, e88134. [CrossRef]

33. Monistero, V.; Barberio, A.; Biscarini, F.; Cremonesi, P.; Castiglioni, B.; Graber, H.U.; Bottini, E.; Ceballos-Marques, A.; Kroemker, V.; Petzer, I.M.; et al. Different distribution of antimicrobial resistance genes and virulence profiles of *Staphylococcus aureus* strains isolated from clinical mastitis in six countries. *J. Dairy Sci.* **2020**, *103*, 3431–3446. [CrossRef]

34. Guimarães, F.F.; Manzi, M.P.; Joaquim, S.F.; Richini-Pereira, V.B.; Langoni, H. Short communication: Outbreak of methicillin-resistant *Staphylococcus aureus* (MRSA)-associated mastitis in a closed dairy herd. *J. Dairy Sci.* **2017**, *100*, 726–730. [CrossRef] [PubMed]

35. Patel, K.; Godden, S.M.; Royster, E.E.; Crooker, B.A.; Johnson, T.J.; Smith, E.A.; Sreevatsan, S. Prevalence, antibiotic resistance, virulence and genetic diversity of *Staphylococcus aureus* isolated from bulk tank milk samples of U.S. dairy herds. *BMC Genom.* **2021**, *22*, 1–13. [CrossRef] [PubMed]

36. Pacha, P.A.; Munoz, M.A.; Gonzalez-Rocha, G.; San Martin, I.; Quezada-Aguluz, M.; Aguayo-Reyes, A.; Bello-Toledo, H.; Latorre, A.A. Molecular diversity of *Staphylococcus aureus* and the role of milking equipment adherences or biofilm as a source for bulk tank milk contamination. *J. Dairy Sci.* **2021**, *104*, 3522–3531. [CrossRef] [PubMed]

37. Middleton, J.R.; Fox, L.K.; Gay, J.M.; Tyler, J.W.; Besser, T.E. Use of pulsed-field gel electrophoresis for detecting differences in *Staphylococcus aureus* strain populations between dairy herds with different cattle importation practices. *Epidemiol. Infect.* **2002**, *129*, 387–395. [CrossRef]

38. Page, S.W.; Gautier, P. Use of antimicrobial agents in livestock. *Rev. Sci. Tech.-OIE* **2012**, *31*, 145–188. [CrossRef]

39. Haveri, M.; Ristolöf, A.; Rantalä, L.; Pyörälä, S. Virulence genes of bovine *Staphylococcus aureus* from persistent and nonpersistent intramammary infections with different clinical characteristics. *J. Appl. Microbiol.* **2007**, *103*, 993–1000. [CrossRef]

40. NMC. *Laboratory Handbook on Bovine Mastitis*; National Mastitis Council: Madison, WI, USA, 2017; 148p.

41. Tomazi, T.; Freug, G.; Alves, B.G.; de Souza Filho, A.F.; Heinemann, M.B.; Veiga dos Santos, M. Genotyping and antimicrobial resistance of *Streptococcus uberis* isolated from bovine clinical mastitis. *PLoS ONE* **2019**, *14*, e0227319. [CrossRef]

42. Harrmsen, D.; Claus, H.; Witte, W.; Rothgänger, J.; Claus, H.; Turnwald, D.; Vogel, U. Typing of methicillin-resistant *Staphylococcus aureus* in a university hospital setting by using novel software for spa repeat determination and database management. *J. Clin. Microbiol.* **2003**, *41*, 5442–5448. [CrossRef]